Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance
NCT ID: NCT03093506
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
25 participants
INTERVENTIONAL
2011-09-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Higher doses of rhEpo is known to increase cognitive performance, but it is not clear if lower doses of rhEpo have similar effects. A second purpose of the present study is to determine if micro-dose as well as low-dose rhEpo increases cognitive performance.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone?
NCT05964920
Identifying Biological Markers for Altitude Exposure and Use of Recombinant Human Erythropoietin (rHuEPO)
NCT04227665
Physical Exercise as a Sustainability Tool in Men With Dysmetabolic Hypogonadism
NCT06094036
Testosterone-induced Muscle Memory and Underlying Mechanisms
NCT06188767
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
NCT05773183
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
On the first day before administration of rhEpo and after the four weeks' treatment the subjects are undergoing two cognitive performance-tests, Raven Standard Progressive Matrices (Raven), and Number Finder (NUFI). Weekly semi-structured interviews are conducted by a blinded interviewer focusing on experienced change in cognitive performance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low-dose rhEpo
RhEpo 60IU/kg/week
Low-dose rhEpo
60IU/kg/week
Micro-dose rhEpo
RhEpo 20IU/kg/week
Micro-dose rhEpo
20IU/kg/week
Placebo Control
Saline
Placebo Control
Saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low-dose rhEpo
60IU/kg/week
Micro-dose rhEpo
20IU/kg/week
Placebo Control
Saline
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weekly exercise for 0-5 hours
Exclusion Criteria
* Earlier use of performance-enhancing drugs
* Elite athletes
* Presence of cardiovascular or metabolic disease
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bispebjerg Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Soeren Lundgaard Larsen
Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Soeren L. Larsen
Role: PRINCIPAL_INVESTIGATOR
Bispebjerg Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Copenhagen University Hospital Bispebjerg, Department of Anaesthesiology
Copenhagen, Kbh NV, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Plenge U, Belhage B, Guadalupe-Grau A, Andersen PR, Lundby C, Dela F, Stride N, Pott FC, Helge JW, Boushel R. Erythropoietin treatment enhances muscle mitochondrial capacity in humans. Front Physiol. 2012 Mar 13;3:50. doi: 10.3389/fphys.2012.00050. eCollection 2012.
Viuff SL, Plenge U, Belhage B, Boushel R, Koester T. Effects of low-dose recombinant human erythropoietin treatment on cognitive performance. Dan Med J. 2017 Sep;64(9):A5403.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-1-2011-098
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.